FELDAN THERAPEUTICS FORMS A SCIENTIFIC ADVISORY BOARD AND EXPANDS ITS LEADERSHIP TEAM
by Feldan Therapeutics on Jan 14,2021
Quebec City, Canada, January 14, 2021 – Feldan Therapeutics, a biotechnology company focusing on the development of therapeutics based on the intracellular delivery of proteins and peptides, announces the creation of a scientific advisory board and the appointment of an Acting Vice-President, Drug Development.
“I am glad to welcome a group of highly experienced scientists having extensive clinical development and executive management experience on our scientific advisory board, which will be pivotal in providing our team with key inputs to advance our clinical programs,” said François-Thomas Michaud, co-founder and chief executive officer of Feldan. “Our priority as a leading company in the field of intracellular delivery is that patients benefit from innovative medicines made possible through the use of our technology, and we are happy to work with renowned experts who share our vision and will help us achieve our goal.”
“I am also pleased to announce the appointment of Dr. Luc Vachon as Acting Vice-President of Drug Development,” added Mr. Michaud. “Dr. Vachon joined our management team a few months ago, and his long track record in drug development is already showing great results in accelerating our preclinical achievements and forthcoming clinical development. Working with Dr. Vachon will solidify Feldan’s clinical expertise and strategy, which are crucial as we move toward pre-IND/CTA filing.”
Dr. Luc Vachon has more than 30 years of experience in drug development, covering all phases and including translating preclinical research into first-in-humans Phase I and early proof-of-concept Phase II studies in patients, large multicentre Phase III and registration trials. His scientific, clinical, regulatory and corporate experience has been acquired through programs conducted in Canada, USA and Europe.
The new scientific advisory board is composed of:
Robert J. Wills, PhD, Chairman of CymaBay Therapeutics’ board of directors
Dr. Wills has more than 35 years of experience in the pharmaceutical industry, including more than 25 years at Johnson & Johnson, where he held positions as Senior Vice-President of Global Development, Vice-President of Alliance Management and member of the R&D board of directors. He has been responsible for the R&D pipeline and for managing worldwide strategic alliances for the pharmaceutical group, playing an active role in the negotiations of these alliances. Dr. Wills also served on several of the company’s boards and key decision-making committees.
Christopher A. Rhodes, PhD, CEO and founder of Drug Delivery Experts
Dr. Rhodes is a pharmaceutical scientist with more than 25 years of experience in developing complex formulations and delivery systems. Dr. Rhodes played a key role in the development of various commercial products and led translational research on delivery systems, including nasal, pulmonary and oral administration, as well as transdermal microporation technologies.
Jean-Michel Gries, PharmD, PhD, Chief Research and Development Officer at Kodikaz
Dr. Gries is an accomplished drug development executive. His successes in the drug development space cover both early stage (with more than 275 INDs) and late stage (15+ NDAs, 7 ANDAs). As a business executive, Dr. Gries helped create nine companies (two of which are now public) via 26 asset acquisitions. Dr. Gries has had exposure over a broad range of disease areas: oncology, inflammation and pain, the central nervous system, metabolism, cardio-renal syndrome, anti-infectives (including HIV and HCV), dermatology, ophthalmology, genito-urinary and gastroenterology.
Murray Webb, PhD, Vice President, Translational Science at Eupraxia Pharmaceuticals
Dr. Webb has more than 25 years of drug discovery and development experience in both industrial and academic settings, with a focus on the conduct and management of translational preclinical studies supporting the entry of novel drugs into clinical trials. This expertise includes an extensive background in in vivo efficacy, pharmacodynamics, pharmacokinetic studies, biodistribution studies, toxicology studies, drug combination studies and natural products. Dr. Webb also has expertise in the regulatory requirements for novel oncology in clinical testing and has initiated and managed Phase I cancer clinical trials.
Feldan specializes in the development of treatments based on the intracellular delivery of proteins and peptides, with a therapeutic pipeline focused on diseases affecting lungs and skin. The company is behind the design of a proprietary peptide-based intracellular delivery technology that enables safe and efficient intracellular delivery of multiple therapeutic compounds and unlocks the development of a new generation of therapies.
For more information: www.feldan.com
Francois-Thomas Michaud, PhD. Eng.
Chief Executive Officer
Feldan Therapeutics, Inc.
T: +1 418-872-7277